AbbVie Inc. Average Days of Receivables

Average Days of Receivables of ABBV for past 10 years: annual, quarterly and twelve month trailing (TTM) including Average Days of Receivables growth rates and interactive chart.


Highlights and Quick Summary

  • Annual Average Days of Receivables for 2019 was 59.56 (a -0.74% decrease from previous year)
  • Annual Average Days of Receivables for 2018 was 60.0 (a -8.84% decrease from previous year)
  • Annual Average Days of Receivables for 2017 was 65.82 (a -2.83% decrease from previous year)
  • Twelve month Average Days of Receivables ending December 30, 2019 was 59.56 (a -3.0% decrease compared to previous quarter)
  • Twelve month trailing Average Days of Receivables decreased by -6.21% year-over-year
Trailing Average Days of Receivables for the last four month:
30 Dec '19 29 Sep '19 29 Jun '19 30 Mar '19
59.56 61.4 61.33 63.5
Visit stockrow.com/ABBV for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Average Days of Receivables of AbbVie Inc.

Most recent Average Days of Receivablesof ABBV including historical data for past 10 years.

Interactive Chart of Average Days of Receivables of AbbVie Inc.

AbbVie Inc. Average Days of Receivables for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2019 59.56
2018 60.0
2017 65.82
2016 67.74
2015 75.53
2014 68.3
2013 93.3
2012 85.35
2011 79.87
2010 78.73
2009 0.0

Business Profile of AbbVie Inc.

Sector: Medical
Industry: Drugs
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. It offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behcet's diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenstrom's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides KALETRA, an anti-human immunodeficiency virus (HIV)-1 medicine used with other anti-HIV-1 medications to maintain viral suppression in HIV-1 patients; NORVIR, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and SYNAGIS to prevent respiratory syncytial virus infection at-risk infants. In addition, it offers AndroGel, a testosterone replacement therapy; CREON, a pancreatic enzyme therapy; Synthroid to treat hypothyroidism; and Lupron to treat prostate cancer, endometriosis, and central precocious puberty, as well as anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product; and ORILISSA, a non-peptide molecule gonadotropin-releasing hormone antagonist. It has collaborations with Alector, Inc.; Janssen Biotech, Inc.; Galapagos; Bristol-Myers Squibb Company; Calico Life Sciences LLC; Cystic Fibrosis Foundation; Dragonfly Therapeutics, Inc.; and Pan-Canadian Pharmaceutical Alliance. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.